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Abstract
Rationale and Objectives—As breast MRI use grows, benchmark performance parameters are
needed for auditing and quality assurance purposes. We describe the variation in breast MRI
abnormal interpretation rates (AIRs) by clinical indication among a large sample of U.S.
community practices.
Materials and Methods—We analyzed data from 41 facilities across five Breast Cancer
Surveillance Consortium imaging registries. Each registry obtained IRB approval for this HIPAA
compliant analysis. We included 11,654 breast MRI exams conducted in 2005–2010 among
women aged 18–79 years. We categorized clinical indications as: 1) screening; 2) extent of
disease; 3) diagnostic (e.g., breast symptoms); and 4) other (e.g., short-interval follow-up). We
characterized assessments as positive (i.e., BI-RADS 0, 4, and 5) or negative (i.e., BI-RADS 1, 2,
6), and provide results with BI-RADS 3 categorized as positive and as negative. We tested for
differences in AIRs across clinical indications both unadjusted and adjusted for patient
characteristics and registry, and assessed for changes in AIRs by indication over time.
Results—When categorizing BI-RADS 3 as positive, AIRs were 21.0% (95% CI: 19.8, 22.3) for
screening, 31.7% (95% CI: 29.6, 33.8) for extent of disease, 29.7% (95% CI: 28.3, 31.1) for
diagnostic, and 27.4% (95% CI: 25.0, 29.8) for other indications (p<0.0001). When categorizing
BI-RADS 3 as negative, AIRs were 10.5% (95% CI: 9.5, 11.4) for screening, 21.8% (95% CI:
19.9, 23.6) for extent of disease, 17.7% (95% CI: 16.5, 18.8) for diagnostic, and 13.3% (95% CI:
11.6, 15.2) for other indications (p<0.0001). The significant differences in AIRs by indication
persisted even after adjusting for patient characteristics and registry (p<0.0001). In addition, for
most indications, there were no significant changes in AIRs over time.
Conclusion—Breast MRI AIRs differ significantly by clinical indication. Practices should
stratify breast MRI exams by indication for quality assurance and auditing purposes.
Keywords
breast magnetic resonance imaging; audit; quality assurance
INTRODUCTION
Breast magnetic resonance imaging (MRI) is the most sensitive modality for detecting breast
cancer, often identifying malignancy otherwise occult by mammography, ultrasound, and
clinical breast examination (1). As the technology improves and the interpretation and
reporting by radiologists becomes standardized, breast MRI is used for an increasing number
of purposes, including high-risk screening, evaluation of extent of malignancy, evaluation of
patients with metastatic axillary adenopathy and unknown primary cancer, and surveillance
after cancer treatment (2–9). Moreover, the technology has now become readily available in
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community settings throughout the U.S. with interpretation and reporting completed by both
subspecialty-trained breast imagers and general radiologists (10).
To facilitate consistent reporting of and management recommendations for breast MRI
findings, the American College of Radiology published the first edition of the Breast
Imaging Reporting and Data System (11) MRI lexicon in 2003, with the most recently
revised edition published in 2013 (12). Similar to the previously established BI-RADS
mammography lexicon, the breast MRI lexicon provides common terminology for
describing MRI findings. Standardized use of the lexicon and BI-RADS assessment
categories allows for improved communication among radiologists and clinicians with
regards to suspicious imaging findings and clinical recommendations (13). Recent studies
have shown that the MRI BI-RADS assessment categories can accurately predict the risk of
malignancy (14, 15).
Under the Medicare Improvement for Patients and Providers Act (MIPPA) of 2008, all
radiology practices that bill for the technical component of breast MRI under part B of the
Medicare Physician Fee Schedule must be accredited as of January 1, 2012 to qualify for
reimbursements (16). To be awarded accreditation, practices must meet minimum quality
standards, including mandatory use of MRI BI-RADS lexicon in reporting. In addition,
imaging centers must maintain a medical outcomes audit program to follow-up positive BI-
RADS assessments and correlate pathology results with suspicious imaging findings (17). In
general, medical audits are widely recognized as important and effective quality assurance
tools for improved patient care (18, 19).
Creating and maintaining a medical outcomes audit program for mammography can be
difficult for community radiology practices without robust linkages to pathology and
oncology databases (19). It is expected that similar challenges will affect the development of
breast MRI outcomes audits, and practices will need to rely upon data that are readily
available, such as clinical indications and image-guided biopsy results, to begin developing
medical audit programs. Given the requirement for standardized use of MRI BI-RADS
assessments, overall abnormal interpretation (i.e., recall) rates for breast MRI (recorded as a
proportion of MRI exams with positive BI-RADS assessments) are realistic audit parameters
readily determined by most community radiology practices developing breast MRI quality
assurance programs.
Our study objective was to estimate abnormal interpretation rates (AIRs) overall and by
clinical indications for breast MRI encountered in routine community practice. We provide a
descriptive analysis of all breast MRI exams performed across a geographically diverse set
of radiology practices over a six-year period. Based on our experience with mammography
audits, we hypothesized that the proportion of positive BI-RADS assessments differs for
screening versus diagnostic MRI exams.
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Each of the National Cancer Institute-funded Breast Cancer Surveillance Consortium
(BCSC) registries sends data for breast MRI exams to a central Statistical Coordinating
Center (SCC) for pooled analyses. Each registry and the SCC follow previously reported
data management and quality control procedures to ensure accurate data collection across
registries (20). Each registry and the SCC obtain institutional review board approval for
either passive or active patient consent or waiver of consent, linkage of patient
characteristics to imaging-related outcomes, and performance of statistical analyses and
results reporting. The SCC and each registry have a Federal Certificate of Confidentiality
and other protections for the identity of individual women, physicians, and practices that are
subjects of this research. All study procedures were compliant with the Health Insurance
Portability and Accountability Act.
For this descriptive analysis, we used data from five breast imaging registries of the BCSC:
the San Francisco Mammography Registry, Vermont Breast Cancer Surveillance System,
New Hampshire Mammography Network, Carolina Mammography Registry, and Group
Health Cooperative (Washington State). These registries comprise a geographically diverse
group of breast imaging facilities in U.S. community settings that prospectively collect
patient demographic and clinical information and breast imaging interpretation data as part
of routine clinical care. A total of 41 individual imaging facilities across the five registries
provided breast MRI data.
Study Population
We included data from all breast MRI exams conducted in 2005–2010 among women aged
18–79 years with reported clinical indication(s) and final BI-RADS assessment across the
five BCSC registries. The registries collected standardized data on breast MRI exams,
including the clinical indication(s) for the exam and the final BI-RADS assessments for each
breast, from electronic data systems, billing information, and abstraction of radiology
reports. Patient risk factor information was obtained at the time of the MRI exam or from the
most recent mammogram within one year prior to the breast MRI exam, including: the
patient’s age, race/ethnicity, any personal history of breast cancer (self-reported or via
linkage with tumor registries), family history (first degree relative) of breast cancer, and the
reported mammographic BI-RADS breast density.
Clinical Indication Categorization
We stratified reported clinical indications for breast MRI into one of the following four
categories: 1) screening (i.e., asymptomatic); 2) extent of disease; 3) diagnostic; and 4)
other. Our “diagnostic” indication category included MRI exams performed for additional
evaluation of a recent abnormality identified by mammography or ultrasound, evaluation of
specific breast symptoms, and differentiation of cancer recurrence from post-surgical scar.
Our “other” indication category included MRI exams performed for short interval follow-up
of a probably benign MRI finding, evaluation of treatment response to neoadjuvant
chemotherapy, and all other recorded indications not conforming to any other indication
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category. For the minority of exams with multiple reported clinical indications (11%), we
categorized clinical indication using the following hierarchy to isolate true screening breast
MRI examinations in asymptomatic women from examinations performed for other reasons:
1) extent of disease; 2) evaluation of treatment response to neoadjuvant chemotherapy (=
other); 3) axillary adenopathy of unknown primary (= other); 4) additional evaluation of
recent abnormality on another breast imaging modality (= diagnostic); 5) evaluation of
breast problem (= diagnostic); 6) differentiation of cancer recurrence from post-surgical scar
(= diagnostic); 7) short interval follow-up of prior breast MRI examination (= other); 8)
screening; and 9) other.
BI-RADS Assessment Categorization
We characterized overall assessments as either positive (i.e., needing further initial or short-
term evaluation; BI-RADS 0, 3, 4, and 5) or negative (i.e., no further imaging evaluation
needed; BI-RADS 1, 2, 6). We present results by categorizing BI-RADS 3 assessments as
both positive and negative. The dichotomous or binary categorization of BI-RADS
assessments allows for calculation of AIRs defined as the proportion of examinations with
positive assessments by study clinical indication.
We included both unilateral and bilateral breast MRI exams in our analysis. Each breast in
bilateral breast MRI exams was given a separate BI-RADS assessment. We categorized BI-
RADS assessment as the highest order for the examination, and used the following BI-
RADS assessment hierarchy: 5 > 4 > 3 > 0 > 6 > 2 > 1. Therefore, if a suspicious
abnormality (BI-RADS 4) was identified in one breast but no abnormality was identified in
the other (BI-RADS 1), then the overall exam assessment would be BI-RADS 4. Similarly,
if an additional suspicious abnormality (BI-RADS 4) was identified in a patient with known,
biopsy-proven malignancy (BI-RADS 6), then the overall exam assessment would be BI-
RADS 4 since additional diagnostic work-up is recommended (it is assumed that BI-RADS
6 assessments do not require additional diagnostic work-up since the malignancy has already
been proven by tissue sampling).
Statistical Analysis
We performed all analyses using SAS® Version 9.2 (SAS Institute, Cary, NC). Our
univariate descriptive statistics included frequencies of the patient characteristics (age, race/
ethnicity, family history of breast cancer, personal history of breast cancer, and BI-RADS
breast density on mammography) stratified by four clinical indications. We calculated 95%
exact confidence intervals for the BI-RADS assessment and used the Pearson chi-square test
to identify statistically significant differences in positive versus negative BI-RADS
assessment across clinical indications. In multivariate analyses, we used a logistic regression
model to adjust for BCSC registry as well as patient age, race/ethnicity, family history of
breast cancer, personal history of breast cancer, and mammographic breast density. Finally,
we performed the Cochran-Armitage test for trend to identify significant changes in breast
MRI AIRs by clinical indication over time. We considered a two-sided p<0.05 as
statistically significant.
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Between 2005 and 2010, a total of 15,242 breast MRI exams were performed across five
BCSC breast imaging registries. Of these, 3,533 exams (23%, 3,533/15,242) did not meet
our inclusion criteria and we excluded these from our analysis (589 exams due to patient age
> 79 years-old, 2,451 exams due to missing clinical indication, 493 exams due to missing
BI-RADS assessments, and 55 exams performed to evaluate for implant rupture). Thus, we
included a total of 11,654 breast MRI exams performed between 2005 and 2010 in our
analysis.
The characteristics of patients undergoing breast MRI exams during the study period are
described by clinical indication in Table 1. Briefly, 36.9% (4300/11654) of breast MRI
exams were performed for diagnostic purposes, 34.2% (3989/11654) were performed for
screening, 16.8% (1954/11654) were performed to evaluate extent of disease among newly
diagnosed breast cancer patients, and 12.1% (1411/11654) were performed for other clinical
indications. The majority of breast MRI exams were performed among women who are in
the routine age-based mammographic screening population, aged 40 to 79 years (82.4%,
9599/11654). The majority of breast MRI exams were performed among Caucasian women
(83.9%, 8973/10689), women with a personal history of breast cancer (74.9%, 6114/8166),
women without a first-degree family history of breast cancer (63.8%, 7054/11050), and
women with heterogeneously or extremely dense breasts on mammography (65.7%,
5414/8242).
MRI BI-RADS Assessments by Clinical Indication
We provide a detailed distribution of MRI BI-RADS assessments by clinical indication in
Table 2. The overall proportion of breast MRI exams with positive assessments differed
across clinical indications. When categorizing BI-RADS 3 assessments as positive, AIRs
were 21.0% (839/3989; 95% CI: 19.8, 22.3) for screening exams, 31.7% (619/1954; 95%
CI: 29.6, 33.8) for extent of disease exams, 29.7% (1276/4300; 95% CI: 28.3, 31.1) for
diagnostic exams, and 27.4% (386/1411; 95% CI: 25.0, 29.8) for exams done for other
indications (p<0.0001). When categorizing BI-RADS 3 assessments as negative, the AIRs
declined to 10.5% (417/3989; 95% CI: 9.5, 11.4) for screening exams, 21.8% (425/1954;
95% CI: 19.9, 23.6) for extent of disease exams, 17.7% (759/4300; 95% CI: 16.5, 18.8) for
diagnostic exams, and 13.3% (188/1411; 95% CI: 11.6, 15.2) for exams done for other
indications (p<0.0001). The significant association between AIR and clinical indication
persisted even after adjusting for BCSC registry, patient age, race/ethnicity, family history
of breast cancer, personal history of breast cancer, and mammographic breast density in our
multiple logistic regression (p<0.0001).
We provide a trend analysis of breast MRI AIRs by indication over time in Table 3. We did
not find any significant changes in AIRs for most indications over time regardless of
whether BI-RADS 3 assessments were categorized as positive or negative. The exception
was breast MRI AIR for diagnostic indications, which significantly decreased over time
when BI-RADS 3 assessments were categorized as negative (p<0.0001). However, this trend
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bordered on significant when BI-RADS 3 assessments were re-categorized as positive
(p=0.06).
DISCUSSION
Our study is the first to report proportions of positive BI-RADS assessments by clinical
indication for breast MRI exams performed across a large, geographically diverse set of U.S.
radiology practices over multiple years. Since positive BI-RADS assessments suggest that
further imaging evaluation or work-up is required, our reported proportions of positive BI-
RADS assessments also constitute overall average abnormal interpretation (i.e., recall) rates.
We found that the rate was lower for breast MRI exams conducted for screening compared
to exams conducted for diagnostic work-up or extent of disease. Given statistical
significance in the difference in AIRs across clinical indications even after adjusting for
multiple covariates, radiology practices should audit screening breast MRI exams separately
from diagnostic and extent of disease breast MRI exams.
Our conclusion, that AIRs for breast MRI exams vary by indication, is consistent with
previous studies demonstrating significantly different BI-RADS outcomes for diagnostic
mammography compared with screening mammography, with diagnostic exams defined as
those performed for indications other than screening asymptomatic women (21–23). Similar
to mammography, AIRs for breast MRI are higher for non-screening examinations than
screening examinations. However, unlike screening and diagnostic mammography exams,
which are already categorized as different types of exams for administrative and billing
purposes, there is currently no such delineation by clinical indication for breast MRI exams.
Since the same MR sequences are obtained regardless of indication, all breast MRI exams
are treated the same for scheduling and billing purposes. Our findings, therefore, suggest
that capturing the clinical indication for breast MRI exams at the practice level will be
critical to the development of accurate breast MRI audit and quality assurance programs.
Prior data regarding population-based breast MRI AIRs have been limited to those from
Europe. For example, a population-based screening study from the UK demonstrated a 10%
AIR for screening breast MRI (24). However, this study involved only 649 women age 35–
49 years in a clinical trial setting, with inclusion of women with at least a 60% chance of
carrying BRCA mutations and exclusion of women with a prior breast cancer history (25).
In comparison, our study includes data from 11,654 MRI examinations in the U.S. among
women aged 18 –79 years in real-world community practice settings, without rigid study
inclusion and exclusion criteria. Moreover, we provide average AIRs among a large,
national sample of practices for all other clinical indications for breast MRI exams beyond
asymptomatic screening.
Our analysis is also the first to describe trends in breast MRI interpretation by clinical
indication over several years. We found that the average annual breast MRI AIRs for most
clinical indications did not change significantly over time. The one exception was the trend
of AIRs for diagnostic indications, which decreased over time if BI-RADS 3 assessments
were categorized as negative. This suggests that community radiologists in the U.S. may be
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improving in their interpretive performance of breast MRI exams indicated for diagnostic
purposes with increasing experience.
While our reported proportion of positive BI-RADS assessments and AIRs represent
performance in U.S. community settings, it should not be inferred that these are
recommended targets for performance. The issues of defining standards of care or creating
performance benchmarks and guidelines are beyond the scope of this work. Rather, our
reported measures are a starting point for such discussions, and can be used as one source of
information for examining variation in breast MRI BI-RADS assessments in U.S.
community practice. Yet, given the sparse available data to which practices and radiologists
may compare their breast MRI performance, our data can serve as “ballpark” figures from
large aggregate averages that may be used by clinical practices to gauge their AIRs by
clinical indication observed in their facility and individual audits, for the purpose of
continuous quality improvement.
A major strength of our study is the large sample of breast MRI data from diverse
community radiology practices across different geographic regions. Another major strength
is that we consider scenarios where BI-RADS 3 assessments are classified as either positive
or negative, accounting for their likely variable categorization across practices. Moreover,
we adjust for patient demographic and clinical characteristics that are potential confounders
for breast MRI AIR, including age, race/ethnicity, family history of breast cancer, personal
history of breast cancer, and BI-RADS breast density (26–29). However, there are
limitations to our analysis. First, we did not evaluate how physician characteristics such as
interpretative volume and experience level or facility type influenced the proportion of
positive MRI BI-RADS assessments. Second, we were unable to determine outcomes
measures such as cancer detection rate or positive predictive value (PPV) as we do not yet
have complete cancer capture for most of these exams due to lags in cancer registry
reporting. Acceptability of reported AIRs may depend upon concomitant acceptability of
these outcomes. Third, we did not evaluate the effect of technical parameters, such as
magnetic field strength, on breast MRI AIR. However, a recent survey demonstrated that
94% of all BCSC facilities met both ACRIN and European Society of Breast Imaging
technical standards for breast MRI equipment, including the use of ≥ 1.5 Tesla field strength
for all breast MRI exams (30).
Finally, we assume that positive BI-RADS assessments were associated with the proper
clinical management recommendations for suspicious imaging findings requiring further
diagnostic work-up, and that women with negative assessments were not recalled for further
workup. Yet, prior studies with regards to application of mammography BI-RADS shortly
after its adoption into clinical practice demonstrated inconsistencies between the
assessments and expected clinical management recommendations (31–33). Given the
relatively recent adoption of breast MRI and the ACR breast MRI BI-RADS lexicon into
clinical practice, there may be inconsistencies between MRI BI-RADS and clinical
management recommendations in community practice. Therefore, as a next step, we are
planning an analysis of the agreement between recorded MRI BI-RADS assessments and
recorded clinical management recommendations.
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In conclusion, we present data on the proportion of positive BI-RADS assessments by
clinical indication for breast MRI examinations among a geographically diverse set of
radiology practices across the U.S. These measures can be used as first available figures by
individual breast imaging practices and radiologists to compare with their own performance
as part of periodic mandatory audits and quality improvement initiatives. Our report, based
on a large national sample of imaging practices, can also be used as a starting point by
governing bodies and breast imaging experts who aim to determine performance
benchmarks for breast MRI exams. Based on our statistically significant findings, radiology
practices should determine and report their breast MRI AIRs stratified by clinical
indications.
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